Sponsor Dossier
Maxx Pharma
Sponsor Dossier for Maxx Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABEVMY
- Brand: DICLOFENAC
- Brand: FULPHILA
- Brand: HULIO
- Brand: NEPEXTO
- Brand: OGIVRI
- Brand: ONGENTYS
- Brand: SEMGLEE
About
Maxx Pharma is an Australian Private Company with ABN 33 629 622 224, registered in Victoria. The company is active on the Australian Business Register.
Portfolio
Maxx Pharma has 10 brands on the ARTG, with 7 indexable brands cleared through the SEO quality gate. Five brands have Product Information on file, 2 brands have at least one PBS-listed item, 6 brands have PBAC outcome records, and 2 brands have AusPAR records on file. Notable brands include ABEVMY, DICLOFENAC, FULPHILA, HULIO, NEPEXTO, OGIVRI, ONGENTYS, SEMGLEE, VAXELIS, and YESINTEK.
Therapeutic focus —
Oncology: 3 brands — Immunology: 2 brands — Infectious Disease: 2 brands — Neurology: 1 brand — Endocrinology: 1 brand — Pain & Anaesthesia: 1 brand
PBS footprint
Two brands in Maxx Pharma's portfolio have at least one PBS-listed item, with the latest PBS schedule date touched being 1 May 2026.
Regulatory activity
Maxx Pharma's most recent PBAC outcome was on 1 July 2025, with 6 brands holding PBAC outcomes on record. The most recent AusPAR was issued on 10 May 2021, with 2 brands holding AusPAR records on file.